Review of automated insulin delivery systems for individuals with type 1 diabetes: tailored solutions for subpopulations

Automated insulin delivery (AID) systems have proven safe and effective in improving glycemic outcomes in individuals with type 1 diabetes. Clinical evaluation of this technology has progressed to large randomized, controlled outpatient studies and recent commercial approval of AID systems for children and adults. However, several challenges remain in improving these systems for different subpopulations (e.g. young children, athletes, pregnant women, seniors, and those with hypoglycemia unawareness). In this review, we highlight the requirements and challenges in AID design for selected subpopulations and discuss current advances from recent clinical studies.

Automated summary

This review highlights the safety and effectiveness of automated insulin delivery systems in individuals with type 1 diabetes, as well as the challenges and requirements for improving these systems for different subpopulations. Recent advances in clinical studies are also discussed.